Telitacicept for the Treatment of Refractory RA

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG

Telitacicept

Telitacicept 160mg qw subcutaneous injection

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Chinese SLE Treatment And Research Group

OTHER